Burns Matteson Capital Management LLC acquired a new position in Axon Enterprise, Inc. (NASDAQ:AXON – Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 684 shares of the biotechnology company’s stock, valued at approximately $214,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in AXON. Natixis bought a new position in shares of Axon Enterprise during the first quarter valued at about $16,237,000. InterOcean Capital Group LLC grew its stake in shares of Axon Enterprise by 47.1% in the first quarter. InterOcean Capital Group LLC now owns 1,568 shares of the biotechnology company’s stock worth $491,000 after purchasing an additional 502 shares during the last quarter. CANADA LIFE ASSURANCE Co grew its stake in shares of Axon Enterprise by 74.2% in the first quarter. CANADA LIFE ASSURANCE Co now owns 89,861 shares of the biotechnology company’s stock worth $28,114,000 after purchasing an additional 38,269 shares during the last quarter. UniSuper Management Pty Ltd grew its stake in shares of Axon Enterprise by 388.4% in the first quarter. UniSuper Management Pty Ltd now owns 3,819 shares of the biotechnology company’s stock worth $1,195,000 after purchasing an additional 3,037 shares during the last quarter. Finally, O Shaughnessy Asset Management LLC grew its stake in shares of Axon Enterprise by 55.4% in the first quarter. O Shaughnessy Asset Management LLC now owns 1,986 shares of the biotechnology company’s stock worth $621,000 after purchasing an additional 708 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.
Insider Buying and Selling
In other Axon Enterprise news, Director Jeri Williams sold 308 shares of Axon Enterprise stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $310.07, for a total value of $95,501.56. Following the completion of the sale, the director now owns 1,607 shares of the company’s stock, valued at approximately $498,282.49. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, Director Jeri Williams sold 308 shares of the business’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $310.07, for a total transaction of $95,501.56. Following the completion of the sale, the director now owns 1,607 shares of the company’s stock, valued at approximately $498,282.49. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, President Joshua Isner sold 44,000 shares of the business’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $309.96, for a total transaction of $13,638,240.00. Following the sale, the president now directly owns 275,843 shares of the company’s stock, valued at approximately $85,500,296.28. The disclosure for this sale can be found here. Insiders sold a total of 89,447 shares of company stock worth $27,684,677 in the last three months. Insiders own 6.10% of the company’s stock.
Axon Enterprise Stock Down 0.7 %
Axon Enterprise (NASDAQ:AXON – Get Free Report) last announced its quarterly earnings data on Friday, May 10th. The biotechnology company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.20. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The company had revenue of $460.74 million during the quarter, compared to analyst estimates of $441.57 million. During the same period in the previous year, the business earned $0.51 EPS. The firm’s revenue for the quarter was up 34.3% on a year-over-year basis. On average, analysts expect that Axon Enterprise, Inc. will post 2.35 EPS for the current year.
Analysts Set New Price Targets
Several research firms recently issued reports on AXON. Jefferies Financial Group began coverage on Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $385.00 target price on the stock. Bank of America began coverage on Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $380.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $400.00 price objective on shares of Axon Enterprise in a report on Tuesday, May 7th. William Blair restated an “outperform” rating on shares of Axon Enterprise in a report on Wednesday, April 24th. Finally, JMP Securities restated a “market outperform” rating and issued a $375.00 price objective on shares of Axon Enterprise in a report on Tuesday, May 7th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $342.54.
Check Out Our Latest Analysis on AXON
About Axon Enterprise
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Read More
- Five stocks we like better than Axon Enterprise
- How to Effectively Use the MarketBeat Ratings Screener
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- 3 Warren Buffett Stocks to Buy Now
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON – Free Report).
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.